Search research articles
Contact Us
Filters
Showing results (231-240 of 431) with videos related to
Page
of 44
Sort By:
Diabetes, Obesity & Metabolism
|
January 23, 2025
Follistatins, activins and inhibins during osteoporosis therapy with denosumab or zoledronate and after their discontinuation
Athanasios D Anastasilakis, Polyzois Makras, Stergios A Polyzos, et al.
Journal of Gastroenterology and Hepatology
|
June 24, 2022
Circulating adiponectin in patients with nonalcoholic fatty liver disease-related liver fibrosis: A systematic review and a meta-analysis
Christina Tontikidou, Evangelia S Makri, Kleo Evripidou, et al.
Journal of Clinical Medicine
|
September 28, 2023
Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab
Athanasios D Anastasilakis, Polyzois Makras, Julien Paccou, et al.
The International Journal of Neuroscience
|
March 4, 2020
Alzheimer's disease and gastrointestinal microbiota; impact of <i>Helicobacter pylori</i> infection involvement
Michael Doulberis, Georgios Kotronis, Dimitra Gialamprinou, et al.
Indian Journal of Endocrinology and Metabolism
|
January 26, 2012
Comparative effects of sibutramine and orlistat on weight loss, glucose metabolism and leptin levels in non-diabetic obese patients: A prospective study
Panagiotis Anagnostis, Despina Selalmatzidou, Michalis Sapranidis, et al.
Annals of Gastroenterology
|
January 16, 2018
<i>Helicobacter pylori</i> infection and esophageal adenocarcinoma: a review and a personal view
Stergios A Polyzos, Christos Zeglinas, Fotini Artemaki, et al.
Endocrine
|
May 21, 2024
Hypogonadism and nonalcoholic fatty liver disease
Kasiani Papadimitriou, Athanasios C Mousiolis, Gesthimani Mintziori, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
February 28, 2017
Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases
Athanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
August 22, 2019
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial
Athanasios D Anastasilakis, Socrates E Papapoulos, Stergios A Polyzos, et al.
Endocrine
|
March 2, 2021
Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion
Athanasios D Anastasilakis, Stergios A Polyzos, Maria P Yavropoulou, et al.
Page
of 44
Search research articles
Search
Showing results (231-240 of 431) with videos related to
Sort By:
Page
of 44
Diabetes, Obesity & Metabolism
|
January 23, 2025
Follistatins, activins and inhibins during osteoporosis therapy with denosumab or zoledronate and after their discontinuation
Athanasios D Anastasilakis, Polyzois Makras, Stergios A Polyzos, et al.
Journal of Gastroenterology and Hepatology
|
June 24, 2022
Circulating adiponectin in patients with nonalcoholic fatty liver disease-related liver fibrosis: A systematic review and a meta-analysis
Christina Tontikidou, Evangelia S Makri, Kleo Evripidou, et al.
Journal of Clinical Medicine
|
September 28, 2023
Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab
Athanasios D Anastasilakis, Polyzois Makras, Julien Paccou, et al.
The International Journal of Neuroscience
|
March 4, 2020
Alzheimer's disease and gastrointestinal microbiota; impact of <i>Helicobacter pylori</i> infection involvement
Michael Doulberis, Georgios Kotronis, Dimitra Gialamprinou, et al.
Indian Journal of Endocrinology and Metabolism
|
January 26, 2012
Comparative effects of sibutramine and orlistat on weight loss, glucose metabolism and leptin levels in non-diabetic obese patients: A prospective study
Panagiotis Anagnostis, Despina Selalmatzidou, Michalis Sapranidis, et al.
Annals of Gastroenterology
|
January 16, 2018
<i>Helicobacter pylori</i> infection and esophageal adenocarcinoma: a review and a personal view
Stergios A Polyzos, Christos Zeglinas, Fotini Artemaki, et al.
Endocrine
|
May 21, 2024
Hypogonadism and nonalcoholic fatty liver disease
Kasiani Papadimitriou, Athanasios C Mousiolis, Gesthimani Mintziori, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
February 28, 2017
Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases
Athanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
August 22, 2019
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial
Athanasios D Anastasilakis, Socrates E Papapoulos, Stergios A Polyzos, et al.
Endocrine
|
March 2, 2021
Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion
Athanasios D Anastasilakis, Stergios A Polyzos, Maria P Yavropoulou, et al.
Page
of 44